Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Foghorn Therapeutics Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 4 Agresta Samuel (Chief Medical Officer) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Sold 311,297 shares @ $8.25, valued at $2.6M
Exercised 311,297 options to buy @ $3.72, valued at $1.2M
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
08/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Foghorn Therapeutics Announces Chief Medical Officer Succession"
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 8-K Investor presentation
Docs: "Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update –Initiating FHD-286 combination study in AML in the third quarter of 2023",
"LARGE MARKET POTENTIAL WELL- FUNDED COLLABORATIONS WITH MAJOR ONCOLOGY PLAYERS SIGNIFICANT VALUE DRIVERS IN 2023"
05/31/2023 4 GOTTSCHALK ADRIAN (CEO) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Gifted 300,000 shares @ $0
05/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Investor presentation
Docs: "Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update –Data from Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma expected in the second quarter of 2023",
"LARGE MARKET POTENTIAL WELL- FUNDED COLLABORATIONS WITH MAJOR ONCOLOGY PLAYERS SIGNIFICANT VALUE DRIVERS IN 2023"
04/24/2023 8-K Quarterly results
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "FOGHORN THERAPEUTICS INC. AMENDED AND RESTATED BYLAWS,",
"Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update - Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial safety and efficacy data expected in the first half of 2023",
"LARGE MARKET POTENTIAL WELL- FUNDED COLLABORATIONS WITH MAJOR ONCOLOGY PLAYERS SIGNIFICANT VALUE DRIVERS IN 2023"
03/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "LARGE MARKET POTENTIAL WELL- FUNDED COLLABORATIONS WITH MAJOR ONCOLOGY PLAYERS SIGNIFICANT VALUE DRIVERS IN 2023"
02/22/2023 4 GOTTSCHALK ADRIAN (CEO) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Gifted 123,479 shares @ $0
Gifted 123,479 shares @ $0
Acquired 4,371 shares @ $0
Disposed of 4,371 shares @ $0
Gifted 4,371 shares @ $0
Gifted 4,371 shares @ $0
Disposed of 184,939 shares @ $0
Acquired 184,939 shares @ $0
02/09/2023 SC 13G/A FMR LLC reports a 7.5% stake in FOGHORN THERAPEUTICS INC
01/30/2023 4 Agresta Samuel (Chief Medical Officer) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Granted 60,000 options to buy @ $8.38, valued at $502.8k
01/30/2023 4 Cavalie Fanny (Chief Strategy/Bus Ops Officer) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Granted 65,000 options to buy @ $8.38, valued at $544.7k
01/30/2023 4 Bellon Steven F. (Chief Scientific Officer) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Granted 100,000 options to buy @ $8.38, valued at $838k
01/30/2023 4 Costa Carlos (Chief People Officer) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Granted 65,000 options to buy @ $8.38, valued at $544.7k
01/30/2023 4 LaCascia Michael (Chief Legal Officer) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Granted 90,000 options to buy @ $8.38, valued at $754.2k
01/30/2023 4 GOTTSCHALK ADRIAN (CEO) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Granted 280,000 options to buy @ $8.38, valued at $2.3M
01/30/2023 4 Reine Allan (CFO) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Granted 90,000 options to buy @ $8.38, valued at $754.2k
01/09/2023 8-K Investor presentation
Docs: "Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023",
"LARGE MARKET POTENTIAL WELL- FUNDED COLLABORATIONS WITH MAJOR ONCOLOGY PLAYERS SIGNIFICANT VALUE DRIVERS IN 2023"
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Investor presentation
Docs: "Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update",
"LARGE MARKET POTENTIAL WELL- FUNDED SIGNIFICANT GLOBAL PARTNERSHIPS EXPERIENCED LEADERSHIP TEAM UPCOMING MILESTONES"
10/27/2022 8-K Quarterly results
10/26/2022 8-K Quarterly results
09/19/2022 4 GOTTSCHALK ADRIAN (CEO) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Exercised 40,000 options to buy @ $0.54, valued at $21.6k
09/14/2022 4 GILL SIMBA (Director) has filed a Form 4 on Foghorn Therapeutics Inc.
Txns: Gifted 47,939 shares @ $0
Exercised 82,000 options to buy @ $0.73, valued at $59.9k
09/13/2022 3/A SMITH IAN F (Director) has filed a Form 3/A on Foghorn Therapeutics Inc.
09/09/2022 3/A PARSHALL B LYNNE (Director) has filed a Form 3/A on Foghorn Therapeutics Inc.
09/09/2022 3/A Costa Carlos (Chief People Officer) has filed a Form 3/A on Foghorn Therapeutics Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy